130 related articles for article (PubMed ID: 27682623)
1. Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma.
Ito K; Okamoto M; Inaguma Y; Okamoto A; Ando M; Ando Y; Tsuge M; Tomono A; Kakumae Y; Hayashi T; Yamada S; Emi N
Oncology; 2016; 91(6):302-310. PubMed ID: 27682623
[TBL] [Abstract][Full Text] [Related]
2. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab.
Kurokawa T; Hase M; Tokuman N; Yoshida T
Hematol Oncol; 2011 Mar; 29(1):5-9. PubMed ID: 20552573
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
6. CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review.
Kakinoki Y; Hashiguchi J; Ishio T; Chiba K; Niino D; Ohshima K
Int J Hematol; 2015 Dec; 102(6):702-8. PubMed ID: 26251099
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
8. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
9. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
[TBL] [Abstract][Full Text] [Related]
10. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
11. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
12. [Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the literature].
Simon Z; Illés A; Miltényi Z; Magyari F; Váróczy L; Péter N; Gergely L
Orv Hetil; 2012 Oct; 153(42):1658-66. PubMed ID: 23063898
[TBL] [Abstract][Full Text] [Related]
13. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
[TBL] [Abstract][Full Text] [Related]
14. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
16. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
19. Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.
Kansara R; Connors JM; Savage KJ; Gerrie AS; Scott DW; Slack GW; Gascoyne RD; Sehn LH; Villa D
Haematologica; 2016 Oct; 101(10):e411-e414. PubMed ID: 27479818
[No Abstract] [Full Text] [Related]
20. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
